Investing

Add as a preferred source on Google

Wells Fargo Raises Zimmer Biomet Rating, Citing Monogram Robot

Zimmer Biomet acquired Monogram Technologies in a 2025 transaction valued at $177 million.

Updated 1 min read
A knee surgery robot stands beside a treatment table in a Warsaw, Indiana, demonstration lab. / EconoTimes.ai (mono)
A knee surgery robot stands beside a treatment table in a Warsaw, Indiana, demonstration lab. / EconoTimes.ai (mono)

Zimmer Biomet’s semi-autonomous Monogram system has FDA clearance, and Wells Fargo cited its potential revenue contribution when it moved the stock to Overweight from Equal Weight Tuesday.

Monogram Technologies became part of Zimmer Biomet in a 2025 transaction valued at $177 million.

The semi-autonomous system received clearance from the Food and Drug Administration (FDA).

Related articles

View all